Literature DB >> 17114906

Long-term effects of elevated gastrin levels on calcitonin secretion.

M F Erdogan1, A Gursoy, M Kulaksizoglu.   

Abstract

Gastrin and pentagastrin stimulate thyroid C cells and elevate serum calcitonin levels. Gastrin levels may be elevated when histamine-2 receptor blockers (H2RB) and/or proton pump inhibitors (PPI) are used, or in patients with pernicious anemia (PA). This study was designed to investigate the long-term effects of elevated gastrin levels on serum calcitonin levels. We conducted a pentagastrin stimulation test to evaluate C cell reserves in patients who had been using PPI and/or H2RB for an extended period, as well as in patients with PA. We compared the results with a healthy control group of similar age and sex. A total of 40 controls (26 women, 24 men) and 25 patients (15 women, 10 men) using H2RB and/or PPI, and 37 patients (24 women, 13 men) with PA were enrolled. The groups were similar in terms of mean age and sex distribution. Mean fasting gastrin levels, and mean baseline and pentagastrin-stimulated calcitonin levels were significantly higher in the H2RB+PPI and PA groups than in controls. No significant differences were observed between the H2RB+PPI and PA groups. There was no correlation between gastrin and calcitonin levels. However, mean calcitonin levels were significantly higher in subjects with high baseline gastrin levels than in controls. The prevalence of autoimmune thyroid disease was 32% in the PA group. Patients with PA and thyroiditis had significantly higher baseline gastrin levels than patients with PA only (p<0.01). PA with autoimmune thyroid disease had also significantly higher baseline and pentagastrin-stimulated calcitonin levels than did PA patients without autoimmune thyroid disease. In conclusion, chronic elevated gastrin levels led to elevated calcitonin levels. Further histopathological studies showing C cell hyperplasia are needed to confirm the mechanism of this relationship.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17114906     DOI: 10.1007/BF03347369

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

1.  C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin.

Authors:  K Kaserer; C Scheuba; N Neuhold; A Weinhäusel; H Vierhapper; O A Haas; B Niederle
Journal:  Am J Surg Pathol       Date:  1998-06       Impact factor: 6.394

2.  Serum calcitonin in hypergastrinaemia due to achlorhydria.

Authors:  J Fahrenkrug; O B Schaffalitzky de Muckadell; J F Rehfeld
Journal:  Acta Endocrinol (Copenh)       Date:  1977-09

3.  The role of serum gastrin in the secretion of calcitonin: studies in patients with pernicious anaemia and in healthy subjects.

Authors:  M Brandsborg; H E Nielsen; O Brandsborg; K J Olsen; N A Løvgreen
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

4.  Omeprazole: calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma.

Authors:  M F Erdoğan; S Güllü; N Başkal; A R Uysal; N Kamel; G Erdoğan
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

5.  Highly selective vagotomy in the rat: effects on bone and mineral metabolism.

Authors:  G Rümenapf; P O Schwille; W Wagner; F P Tiecks; W Fries; D Galewski
Journal:  Scand J Gastroenterol       Date:  1994-03       Impact factor: 2.423

6.  Lack of clinical and physiological relationship between gastrin and calcitonin in man.

Authors:  G Heynen; A Brassine; J C Daubresse; G Ligny; J A Kanis; S Gaspar; P Franchimont
Journal:  Eur J Clin Invest       Date:  1981-08       Impact factor: 4.686

7.  Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients.

Authors:  M Lazzaroni; O Sangaletti; G Bianchi Porro
Journal:  Hepatogastroenterology       Date:  1992-08

8.  Serum concentrations of immunoreactive calcitonin in patients with hypergastrinaemia.

Authors:  C B Lamers; W H Hackeng; T Thien; J H van Tongeren
Journal:  Digestion       Date:  1980       Impact factor: 3.216

9.  Cholecystokinins but not gastrin-17 release calcitonin from thyroid C-cells in the rat.

Authors:  P Persson; T Grunditz; J Axelson; F Sundler; R Håkanson
Journal:  Regul Pept       Date:  1988-05

10.  Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities.

Authors:  A Perry; K Molberg; J Albores-Saavedra
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860

View more
  10 in total

1.  Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma.

Authors:  Fabio Maino; Cristina Dalmiglio; Nicoletta Benenati; Michele Campanile; Tania Pilli; Raffaella Forleo; Lucia Brilli; Cristina Ciuoli; Silvia Cantara; Marco Capezzone; Alessandra Cartocci; Furio Pacini; Maria Grazia Castagna
Journal:  Eur Thyroid J       Date:  2020-10-12

Review 2.  Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?

Authors:  Yang Cao; Xiao-Min Liu
Journal:  Endocrine       Date:  2014-07-18       Impact factor: 3.633

3.  LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Authors:  G H Daniels; L Hegedüs; S P Marso; M A Nauck; B Zinman; R M Bergenstal; J F E Mann; J Derving Karsbøl; A C Moses; J B Buse; R M Tuttle
Journal:  Diabetes Obes Metab       Date:  2015-02-23       Impact factor: 6.577

Review 4.  Thyroid nodule update on diagnosis and management.

Authors:  Shrikant Tamhane; Hossein Gharib
Journal:  Clin Diabetes Endocrinol       Date:  2016-10-03

5.  RETRACTED ARTICLE: Thyroid nodules update in diagnosis and management.

Authors:  Shrikant Tamhane; Hossein Gharib
Journal:  Clin Diabetes Endocrinol       Date:  2015-09-18

6.  No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.

Authors:  S I Sherman; R T Kloos; R M Tuttle; A Pontecorvi; H Völzke; K Harper; C Vance; J T Alston; A L Usborne; K W Sloop; M Lakshmanan
Journal:  Diabet Med       Date:  2018-03       Impact factor: 4.359

Review 7.  The horizon of bone organoid: A perspective on construction and application.

Authors:  Shuangshuang Chen; Xiao Chen; Zhen Geng; Jiacan Su
Journal:  Bioact Mater       Date:  2022-02-05

8.  Serum calcitonin estimation in medullary thyroid cancer: basal or stimulated levels?

Authors:  Chantal Daumerie; Dominique Maiter; Damien Gruson
Journal:  Thyroid Res       Date:  2013-03-14

9.  Calcitonin-secreting pancreatic neuroendocrine tumor in a patient with elevated thyroid fine-needle aspirate calcitonin washout: A case report and review of the literature.

Authors:  Darryl Mason; Robert Leimbach; Robert Kitz; Robert Vietor; Nicole Vietor
Journal:  Clin Case Rep       Date:  2022-01-24

10.  Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer

Authors:  Emine Kartal Baykan; Mehmet Erdoğan
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.